Rachel E. Haurwitz insider trades: Caribou Biosciences (CRBU) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Rachel reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 14, 2025 | CRBU | ↑ Buy | 20,000 | $1.02 | $20K | By Trust | Mar 17, 2025 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CRBU insiders
Open-market trades in the last 12 months
About Rachel E. Haurwitz's insider trades
Rachel E. Haurwitz is President and CEO at Caribou Biosciences (CRBU). Since Mar 14, 2025, Rachel has reported 1 open-market purchase worth $20K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (10 filings), option exercises (4 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CRBU insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.